Santosh Vetticaden
2017
In 2017, Santosh Vetticaden earned a total compensation of $951.3K as Former Interim CEO and CMO at INSYS Therapeutics.
Compensation breakdown
| Option Awards | $622,883 |
|---|---|
| Salary | $150,962 |
| Stock Awards | $177,100 |
| Other | $320 |
| Total | $951,265 |
Vetticaden received $622.9K in option awards, accounting for 65% of the total pay in 2017.
Vetticaden also received $151K in salary, $177.1K in stock awards and $320 in other compensation.
Rankings
In 2017, Santosh Vetticaden's compensation ranked 9,200th out of 14,666 executives tracked by ExecPay. In other words, Vetticaden earned more than 37.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,200 out of 14,666 | 37th |
Division Manufacturing | 3,539 out of 5,772 | 39th |
Major group Chemicals And Allied Products | 1,213 out of 2,075 | 42nd |
Industry group Drugs | 974 out of 1,731 | 44th |
Industry Pharmaceutical Preparations | 765 out of 1,333 | 43rd |
Source: SEC filing on April 16, 2018.
Vetticaden's colleagues
We found five more compensation records of executives who worked with Santosh Vetticaden at INSYS Therapeutics in 2017.
2017
Saeed Motahari
INSYS Therapeutics
Chief Executive Officer
2017
Franc Del Fosse
INSYS Therapeutics
General Counsel
2017
Andrew Long
INSYS Therapeutics
Chief Financial Officer
2017
Darryl Baker
INSYS Therapeutics
Chief Financial Officer
2017
John Kapoor
INSYS Therapeutics